Health

Octapharma USA announces FDA approval of cutaquig 16





Octapharma USA today announced the U.S. Food & Drug Administration (FDA) has approved cutaquig® [Immune globulin, Subcutaneous (Human)-hipp, 16.5% Solution] for the treatment of pediatric patients age 2 and older with primary humoral immunodeficiency (PI). The FDA previously approved cutaquig® for adults with PI.

“The FDA approval provides physicians and families with more treatment options for patients with primary immune disorders, which weaken the immune system and can allow infections and other health issues to occur more easily,” said Roger H. Kobayashi, M.D., Clinical Professor UCLA School of Medicine and National Consultant, Immune Deficiency Foundation. “The FDA approval also provides more flexible options by permitting more frequent or less frequent infusions, which can be advantageous based on a patient’s pharmacokinetic and clinical response.”

Patients and providers have the flexibility to administer cutaquig® at a lower dose more frequently or at a larger dose less frequently if desired. Patients who prefer less frequent injections may have the option of receiving therapy every other week. At the same time, physicians can prescribe daily dosing if patients respond better to more frequent therapy.

Cutaquig® provides enhanced convenience for a wider group of patients who want to customize therapy with their prescriber to best match patient lifestyle needs,” said Octapharma USA President Flemming Nielsen. “Octapharma is committed to providing people with immune disorders the life-saving therapies they need. Both the addition of the pediatric indication and the flexible dosing illustrate our commitment to ensure patients have access to lifesaving products that offer a variety of choices for therapy delivery.”

Flemming Nielsen, President, Octapharma USA

The FDA approval of cutaquig® is based on the results of two clinical trials, which observed 75 PI patients, 37 adults and 38 pediatric patients between ages 2 and 17. The patients received weekly infusions with cutaquig® during a 12-week wash-in/wash-out period followed by a 12-month efficacy period. The main objective of the research was to assess the efficacy of cutaquig® in preventing serious bacterial infections, defined as bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia and visceral abscess. No serious bacterial infections were reported.

Read The Full Article Here

SAT: Why Do We Let a Number Take On so
Kerry Godliman On Being A “Good” Parent
Disney College Program: How Your Teen Can Work at Disney
Wharton Snapshot: Advice For Parents
Olivia Munn’s Mother’s Day Was Absolute Mom Goals
Safe Exercises to Try During the Second Trimester of Pregnancy
This Gadget Turns 3 Simple Ingredients Into A Powerful Disinfectant
5 EASY TIPS TO REDUCE BACK PAIN DURING PREGNANCY |
TRYING BEST PARENTING LIFE HACKS-Smart Tips for Parents -NO MORE
Crying, Cooing, Communication: Baby’s First Year
Sharing Your Child’s Photos Online Could Be Harmful
Starting School
My Child, His Imaginary Friend and I…
Principles for Raising a Child or Teen with ADHD with
Health-Tips for Raising Healthy Kids
Advice for Raising Children in Today’s World -Mufti Abu Layth
Recall Alert: Peanut Butter
Boosters Advised For 5-11 y/o
Investigating incidence and clinical features of post-acute sequelae of COVID-19
Researchers investigate gestational diabetes mellitus and its association with maternal
Child Development: Are You Anxious About Autistic Risks?
Autism: Tools To Adapt Yourself To Your Child’s Emotions And Unexpressed Requests
Infant Science and Art Activity at Bright Horizons
Best Spraygrounds and Splash Pads on Long Island
Ryan’s Family Camping Trip and more 1hr fun kids activities
Visual Discrimination Activity With Dot Stickers That’s Simple & Fun